| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500031 | Farmacia Hospitalaria | 2012 | 9 Pages |
Abstract
Patients treated with anidulafungin did not require dose adjustment, unlike those treated with caspofungin or micafungin. The use of anidulafungin is a cost-saving treatment for adult non-neutropaenic patients with IC, which would result in better control of the Spanish pharmacy budget.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
M. GarcÃa-Vargas, M.A. Casado, N. Mir, J.A. Barrueta,